



Teaser This review highlights routinely omitted facts on human coronary morphology and on paradoxical patterns of lipid deposition in initiation of coronary atherosclerosis. The analysis offers an alternative hypothesis on the pathogenesis of coronary atherosclerosis.

Excessive intimal hyperplasia in human coronary arteries before intimal lipid depositions is the initiation of coronary atherosclerosis and constitutes a therapeutic target



Vladimir M. Subbotin

602 Samuel Drive, Madison, WI 53717, USA

The consensus hypothesis on coronary atherosclerosis suggests high LDL-C levels as the major cause and pursues it as the therapeutic target, explicitly assuming: (i) *tunica intima* of human coronaries consists of only one cell layer – endothelium, situated on a thin layer of scarcely cellular matrix; and (ii) subendothelial lipoprotein retention initiates the disease. Facts showed: (i) normal *tunica intima* invariably consists of multiple cellular layers; and (ii) initial lipid depositions occurred in the deepest layers of *tunica intima*. This review suggests that coronary atherosclerosis starts with pathological intimal expansion, resulting in intimal hypoxia and neovascularization from adventitial *vasa vasorum*, facilitating lipoprotein extraction by previously avascular deep intimal tissues. Until the hypothesis incorporates real knowledge, our efforts will probably be off-target.

Vladimir M. Subbotin

studied biology and medicine at the Novosibirsk Medical School, Russia, and obtained his MD degree in 1969. He received his PhD in 1973 on the study of the human placenta under his mentor and father M.Ya. Subbotin. Later he worked at the Russian Academy of Sciences (Академгородок), and as a volunteer at the Novosibirsk Zoo. Upon immigration to the USA in 1991, Vladimir worked at the University of Pittsburgh, Department of Pathology and Thomas E. Starzl Transplantation Institute. In 2000 he joined Mirus Bio Corporation (now Arrowhead Pharmaceuticals) Madison WI, USA, working on preclinical pathology, drug delivery and theoretical approaches to coronary atherosclerosis and cancer.



Introduction

The enormously costly drug discovery process today cannot predict the clinical efficacy or sustainability of prospective drugs because of our failure (or limited ability) to identify the biologic mechanisms of diseases (i.e., disease pathogenesis) [1–5]. I suggest that the same sort of failure has thwarted progress in the therapeutic treatment of coronary artery pathology. Another matter that hinders the progress in studying coronary artery pathology is that the main pathologic alterations occur only after the coronary artery wall undergoes certain age-related differentiation. For example, coronary atherosclerosis can affect the coronary wall only after its *tunica intima* differentiates from a thin, one-cell-layer compartment into a thick, multi-cell-layered compartment, in a process called normal [6] or benign [7–9] diffuse intimal thickening (DIT). This makes it tempting to designate DIT as the beginning of coronary atherosclerosis [10–13]. However, coronary DIT occurs in all human hearts without any exception, as well as in all animals with mass comparable to human body mass, which by default makes coronary DIT a normal physiologic arrangement. This misinterpretation (a phenotype occurring in all representatives without exception is perceived as a pathology, although must be perceived as the norm) could potentially jeopardize drug discovery in two ways: (i) a norm that is misguidedly suggested as pathology could be a false therapeutic target; and (ii) designation of a pathogenic status to an erroneous event could divert our efforts in search for real causation(s).

E-mail address: vladimir.m.subbotin@gmail.com.

This review puts the spotlight on selected coronary diseases and their suggested causes: (i) coronary atherosclerosis (high low-density lipoprotein cholesterol (LDL-C) levels, endothelial dysfunction and inflammation); (ii) re-stenosis following interventions and coronary bifurcation disease (mechanical injury and/or stress); (iii) transplant coronary disease (immunologic damage); (iv) Kawasaki disease (infectious etiology and genetic factors); (v) coronary pathology in Hutchinson–Gilford progeria (synthesis of progerin). The study of each disease is aimed at the particular presumed causation as the therapeutic target. However, growing evidence has showed that increased cell proliferation in the coronary *tunica intima*, transforming normal DIT into excessive intimal hyperplasia or pre-pathologic intimal thickening (pre-PIT), is the initiation of all of the above diseases. Excessive intimal hyperplasia can be itself lethal by narrowing the coronary lumen or becoming complicated by plaque formation. Accumulating evidence shows that excessive cell proliferation in the coronary *tunica intima* can be triggered by a variety of diverse, nonspecific signals. However, studying nonspecific signals in the hope of elucidating normal regulation, and finding a therapeutic target, is unproductive. This review suggests that, unless we change our approach to coronary pathology and concentrate on disease initiation (i.e., on excessive intimal hyperplasia in the coronary *tunica intima*), our research and therapeutic efforts will probably be off-target. This inquiry opens with an analysis of coronary atherosclerosis because it is the most frequent and lethal coronary malady. Because the main goal of this review is to present arguments in favor of coronary cell proliferation as the initiation of all of the above coronary diseases, the arguments on the initiation of coronary atherosclerosis are given in greater detail than those for other coronary pathologies; arguments on other coronary pathologies are grounded on the same reasoning.

Coronary atherosclerosis

Brief history of coronary morphology


Understanding the pathogenesis of any of disease always starts with a construction of undisputed knowledge on an organ's normal morphology and its variations under physiologic conditions. In the field of arterial pathology, the modern understanding of arterial design starts with the pioneering work of Richard Thoma. Over four decades, Thoma published observations and hypotheses in leading pathology journals about the resemblance between normal diffuse intimal hyperplasia (now termed DIT) and arteriosclerotic intimal thickening (now termed PIT) in different segments of the aorta, the coronary artery and other arteries. He has also published articles on similarities between the above structures and morphogenesis leading to the closure of the umbilical artery and the *ductus arteriosus*. In his publications, Thoma uses the German 'Neubildung' or 'Gewebsneubildung' to describe new tissue formation without pathologic transformation [i.e., normal hyperplasia (DIT)]. To describe a diseased hyperplasia (PIT), he adds the terms 'Angiosklerose' and 'Angiomalacie'. Thoma hypothesized that arterial intimal thickening is a physiological adaptation to changing hemodynamic demands [14–17]. In one publication (coauthored by his student N. Kaefer), Thoma suggested that the pathogenesis of arteriosclerosis begins with intimal thickening that is initially adaptive [18] (for a review see [19]). Whether one agrees or not with Thoma's 'first histomechanical laws of the bloodstream' [16], it is undisputed that he laid the foundation for coronary pathology.

Pioneering work of Kapitoline Wolkoff

The same year (1923) the final manuscript of Richard Thoma appeared in *Virchows Archiv* [17], the journal published another groundbreaking report concerning normal postnatal development of the human coronary artery, contributed by Dr Kapitoline Wolkoff (alternatively spelled Kapitolina Volkova) from St Petersburg, Russia. I believe that the significance of this report deserves special attention. For the first time, Wolkoff showed that normal human epicardial coronary arteries undergo postnatal developmental changes, gradually transforming their morphology from the after birth design to an adult architecture at an age of 15–30 years. (A personal note: I often cite works that are old. I become so preoccupied with an idea that I must find out who first discovered the facts. However, regardless of personal compulsion, I believe that if someone has overlooked crucial information published a hundred years ago they should update their knowledge). In particular, Wolkoff showed that the coronary *tunica intima* of young children (e.g., 8.5 months) consists of only 1–2 layers of cells lying on a thin amount of matrix and internal elastic lamina. With age, the number of cell layers in the *tunica intima* increases, reaching 10–15 layers at age 15. This structure then differentiates to the adult design of approximately 25–30 cell layers at age 25–30 years (Fig. 1).

From Wolkoff's descriptions, the structures of *tunica intima* above a *lamina elastica interna* (in German 'Bindegewebsschicht' and 'Elastisch-hyperplastische Schicht') correspond to DIT in the modern literature [6,21]. Wolkoff's publication came from the Department of Pathologic Anatomy of the Institute of Experimental Medicine St Petersburg, Russia, headed by N.N. Anitschkow (alternatively spelled Anichkov), who is famous for his seminal work in experimental atherosclerosis. Dr Wolkoff was a disciple of Anitschkow and a lifelong colleague. A crucial significance of Wolkoff's findings has been acknowledged by Anitschkow in the opening chapter of the prominent book: *Arteriosclerosis: A Survey of the Problem*. In his chapter, Anitschkow writes: "... in evaluating the significance of the thickening of the intima, as observed by various authors, it is important to remember that thickening of the intima also occurs in experimental animals as a purely physiological phenomenon in the process of aging. In this respect, the arteries of some animals exhibit almost the same conditions that are observed in human arteries, as may be seen from Miss Wolkoff's investigation (1924). In the view of the fact that some authors mentioned above did not pay any attention to this circumstance, the experimental results reported by them can be accepted only with very great reservations. This criticism applies only to experimental animals of considerable size, like dogs, which invariably exhibit thickening of the intima as a sign of aging..." [22]. Anitschkow referred to Wolkoff's 1923 publication [20] and the second article Wolkoff published in *Virchows Archiv* in 1924 that compared her previous observations of the human coronary artery [20] with those of the arterial morphology of animals [23]. The quotation above showed that the greatest authority in the field suggested that researchers, who were not aware of normal coronary artery intimal thickening in humans and animals, simply cannot be trusted in their results and conclusions. One might expect that such a straightforward warning by the most respectable scientist in the field would not be missed or forgotten.

The following years brought numerous publications on coronary artery design in humans and large mammals. All of them

**FIGURE 1**

Selected drawing of human coronary arteries adapted, with permission, from [20]. (a) 8.5 months, (b) 15 years, (c) 32 years (all females). Red bars indicate the thickness of the *tunica intima*. The original article does not show microscopic magnifications; however they could be inferred as: (a) and (b) $\times 400$; (c) $\times 200$. Source: Reproduced, with permission, from [20].

unanimously confirmed the same facts: the *tunica intima* of coronary arteries of humans and large mammals invariably develops under physiologic conditions into normal intimal hyperplasia or DIT [24–47]. This arterial morphogenesis was particularly well described in great detail by French [25–27], Bálint [42], Velican [28–40] and Cucu [46,47]. Therefore, has knowledge on coronary morphology prevailed and the misinterpretation been resolved?

Known facts on human coronary morphology continue to be ignored in spite of accumulated evidence


Reality is surprising: known facts on coronary artery morphology continue to be ignored in coronary research. Furthermore, in 1989, the renowned UK pathologist Collin L. Berry in the monograph *Diseases of the Arterial Wall* alerted the research community again: “There is a considerable body of literature on the significance of what have usually been described as ‘endothelial cushions’, mainly in coronary arteries (see Robertson for review of early literature). Robertson concluded that the lesions, which could be found in other arteries, were not related to subsequent atherosclerosis but were normal growth phenomenon. These studies however, and the subsequent careful work of the Velicans, have been ignored in recent years”. [48].

Unfortunately, Berry’s assessment in the year 1989 remains valid. Facts of normal human coronary morphology (i.e., obligatory development of DIT in human epicardial arteries) continue to be ignored (or overlooked) in scientific publications, for example [49–53], and educational material, for example [54–56]. All mainstream research and educational writings continue to be based on the incorrect assumption that the human coronary *tunica intima* comprises only one cell layer. These omissions could be caused by inertia in medical education and infrequent usage of specialized medical histology textbooks that contain correct information,

including, for example, *Histology for Pathologists* [57]. I would conditionally have agreed with such an interpretation, but not after the year 2002. In 2002, *Virchows Archiv* published a detailed article by Nakashima *et al.* [21], bringing an end to any misinterpretation and doubt on normal human coronary design. This publication contains detailed information on the postnatal developmental morphology of the human coronary artery, particularly of the *tunica intima* (Figs. 2 and 3). Nakashima *et al.* performed the detailed analysis that undoubtedly documented that: (i) the normal adult coronary *tunica intima* is thicker than the *tunica media*; and (ii) the *tunica intima* comprises numerous cell layers of smooth alpha-actin-positive cells, which are arranged in a very dense manner, two-thirds of the intimal thickness, with the cell layer density progressively increasing toward the internal elastic lamina.

This morphologic study was published in *Virchows Archiv* – a most prestigious international journal in pathology – and received notable citation scores: currently 47 (Web of Science) and 81 (Google Scholar). Therefore, one should anticipate that, after this publication in 2002, all studies on coronary atherosclerosis would be grounded on well-documented facts of coronary artery morphology, and all reservations and objections expressed by Anitschkow and Berry should no longer be of concern; but, as my readers have probably already guessed, this is not the case.

To date arteriosclerosis research has taken no cognizance of fundamental facts about human coronary artery morphology
Today, mainstream analyses of the pathogenesis of coronary arteriosclerosis continue to be based on the incorrect information about coronary artery design. No matter how unrealistic it sounds, the facts are stubborn and astonishing. All chief publications presenting theories on the pathogenesis of coronary arteriosclerosis and possible solutions are based on the explicit assumption that

**FIGURE 2**

DIT in proximal coronary arteries. **(a)** Right coronary artery (RCA), 7-day-old female. **(b)** Left anterior descending artery (LAD), 5-year-old female. **(c)** LAD, 15-year-old female. **(d)** LAD, 29-year-old female. Bars in a, b, c and d represent 25 µm, 50 µm, 50 µm and 100 µm, respectively. I represents the intima and M is the media. These microscopic images represent normal morphological changes in coronary arteries from birth to adult (van Gieson stain). Please note that the *tunica intima* of a normal coronary artery is thicker than the *tunica media*.

Source: Reproduced, with permission, from [21].

the *tunica intima* of human coronary arteries consists of only one layer of cells, endothelial cells, situated on a thin layer of acellular (or scarcely cellular) matrix. This incorrect information appeared as written descriptions and as detailed schematics in analyses of the disease pathogenesis and approaches to a cure. To illustrate the above misrepresentation, I have chosen a dozen recent publications that have presented incorrect information as written descriptions and drawings and I encourage my readers to review these articles [58–70]. My conclusions on the erroneous status in this field can be demonstrated by the following figure from one the most recent publications from 2015 [69] (Fig. 4).


At this point I should like invite my readers to review again figures from Nakashima *et al.* [21], which are real microscopic images of human coronary arteries, and compare them to the depiction of the coronary *tunica intima* given here in Fig. 4. My readers do not have to be pathologists to discover a fundamental difference: numerous (25–30) compactly arranged cell layers of the real coronary *tunica intima* puzzlingly disappeared in Fig. 4 [69]. This incorrect representation of coronary morphology has been further repeated by popular medical websites (e.g., Medscape [71]) and is further amplified by science writings (e.g., [72]) and even by the most reputable informational source – *Encyclopedia Britannica* (Fig. 5).

The most recent book on coronary artery disease by J.T. Willerson [74] incorporates the same incorrect representation of coronary

morphology [75]. By contrast, all real microscopic studies of human coronary arteries undoubtedly confirmed that *tunica intima* of epicardial arteries is thicker than *tunica media* and consists of multiple layers of cells [76]. Someone might ask the following question: is an adherence to the correct coronary architecture really that important for coronary atherosclerosis research? Why do I devote so much attention to incorrect writings and schematics that omit real details of coronary *tunica intima* morphology? A general response is that science cannot omit or distort facts. Although it sounds trivial and redundant, this process is important.

Why human coronary tunica intima design must be recognized as a multi-layered cellular compartment

The specific answer as to why human coronary *tunica intima* design must be recognized as a multilayered cellular compartment has been highlighted by another groundbreaking report from Nakashima's group [77]. In this detailed study, Nakashima and coauthors showed that the initiation of coronary atherosclerosis started with lipid depositions in deep layers of the *tunica intima*, which are distal to the coronary lumen and separated from the luminal blood by numerous intimal cell layers and matrix. At the same time, the subendothelial space and the region proximal to the arterial lumen of the *tunica intima* do not show any lipid accumulation. The initial lipid deposition occurred immediately above the internal



Drug Discovery Today

FIGURE 3

Structures and components of diffuse intimal thickening (DIT) in the proximal portion of the right coronary artery (RCA) in adults. (a,b) DIT was demonstrated as a uniformly thickened inner layer (van Gieson). (c) Immunostain for alpha smooth muscle actin. Almost all the cells in the DIT were smooth muscle cells. (d) Immunostain for the macrophage marker HAM56 at the same site as in (c). Only a few intimal and several adventitial cells were positive (arrowheads). I represents the intima, M is the media and A is the adventitia. These microscopic images represent a normal right adult coronary artery in two intersecting planes. Please note that the *tunica intima* of a normal coronary artery is thicker than the *tunica media*.


Source: Reproduced, with permission, from [21].

elastic lamina and is not accompanied by macrophage infiltration. Even with the progression of lipid deposition, lipid accumulation is always greater in deeper *tunica intima* than in surface layers [77,78]. Notably, these deep lipid deposits do not coincide with macrophage infiltration even at Grade 3 PIT with foam cells (Fig. 6).

The facts that Nakashima *et al.* reported [77,78] have placed the sequence of events in a straightforward order: at the Grade 1 fatty streak (Fig. 6d-f) lipids visibly accumulated in the deepest layers of the *tunica intima*, which are distal to the arterial lumen, whereas the subendothelial region and the outer *tunica intima* proximal to the lumen do not show any trace of lipid accumulation. At the Grade 2 fatty streak (Fig. 6g-i) lipid accumulation in the inner (distal to lumen) layers of the *tunica intima* increased, whereas the outer layers proximal to the blood region are either lipid-free or show much less lipid accumulation. At Grade 3 PIT, accumulation of lipids in the outer *tunica intima*, which is distal to the arterial lumen, dominated compared with tissues proximal to the arterial lumen (Fig. 6m-o). The same paradoxical pattern of initial deep lipid deposition in human coronary atherosclerosis was also noted in early publications by Wolff in 1929 [79] and others [80,81]. I wish to emphasize again that the above observations represent initiation of coronary atherosclerosis.

We must direct our attention to the initiation of coronary atherosclerosis when pathologic alterations are potentially reversible

Reviewing the current literature on the pathogenesis of coronary atherosclerosis has shown that chief analyses essentially do not discuss the disease pathogenesis. The word 'pathogenesis' comes from the Greek *pathos* (disease) and *genesis* (creation) and is interpreted as 'the origination and development of a disease' [82] or in plain language 'events from which a disease begins and then progresses'. Logically, all studies that are devoted to atherosclerotic plaque properties (i.e., plaque stability, vulnerability, rupture and thrombosis) are not about initiation or pathogenesis of coronary atherosclerosis but about inevitable complications of end-stages of the disease [83–85]. Understandably, from a lifesaving perspective, we must study atherosclerotic plaque status and plaque vulnerability, rupture and thrombosis, because these features determine morbidity and mortality. Needless to say, many studies of disease pathogenesis aim for prevention and reversal of pathology but, unfortunately, these end-stage manifestations of coronary atherosclerosis are beyond prevention and reversal and are extremely resistant to therapeutic stabilization [83–85]. Although some progress in plaque stabilization and regression has been reported, these pathologic formations are unlikely to be therapeutically curable,

**FIGURE 4**

Classic incorrect presentation of coronary artery morphology. Please note that the *tunica intima* is shown as one layer of endothelial cells covering the acellular matrix. According to this schematic and the corresponding text, all other noninflammatory cells appeared in the *tunica intima* only after atherosclerotic lesion occurred.

Source: Reproduced, with permission, from [69].

with a high probability that these patients will require coronary intervention (for a review see [86]). Again, studies of advanced stages are extremely important because their results help to save lives but it is unlikely that they could bring an understanding of the disease genesis (i.e., to answer questions regarding how and why the disease occurs and how to prevent it). Therefore, we must not pretend that studying atherosclerotic plaque properties is the study of how the disease begins, because, on the contrary, it is how the disease ends. This review aims to analyze mechanisms of the initiation of coronary atherosclerosis (i.e., Grade 1–2 fatty streak and Grade 3 PIT) when lipid accumulation occurs within still viable coronary structures. Attention to the early stages is crucial because pathological alterations at these stages are potentially interruptible and reversible.


The accepted vector of lipid invasion (from coronary luminal blood into the coronary wall) is incoherent

The accepted hypothesis on the initiation of coronary atherosclerosis assumes that lipids invade the coronary wall from the arterial lumen. However, when the hypothesis is combined with undeniable facts on patterns of initial lipid deposition [77–81], it inevitably implies a self-contradictory model in which lipids from the arterial lumen have invaded and accumulated in the distal deeper layers of DIT, thereby passing through the proximal subendothelial region

and the surface layers of DIT, but nevertheless leaving no trace in the proximal tissues. To rationalize this paradoxical distribution pattern, the accepted hypothesis has to be complemented by certain conditions because a parsimonious explanation for such paradoxical patterning does not exist.

From this point forward, I prefer to use to use the term ‘consensus hypothesis’ instead of ‘accepted hypothesis’ for the following reasons. First, it is not known how many scientists accept or reject the hypothesis. Second, the events surrounding the initiation of coronary atherosclerosis were the subjects of very heated and unsettled debates over the disease pathogenesis, a summary of which was termed the ‘consensus statement’ in 1985 [87–91]. The third reason is that I was convinced by a recent publication of Malone and Agutter [92] that the term consensus hypothesis is more appropriate wording that better defines the circumstances. In their writing, Malone and Agutter argue in favor of their hypothesis of the pathogenesis of deep vein thrombosis and appropriately use the word consensus to describe a mainstream hypothesis in their field of research that they opposed.

To reconcile the consensus hypothesis (with lipid invasion from the arterial lumen) with the discovered facts (no initial lipid deposition in tissues proximal to the lumen but visible deposition in tissues distal to the lumen), Nakashima *et al.* invoked an elegant hypothesis [77,78] that incorporates

**FIGURE 5**

Depiction of normal human coronary artery (left) and coronary atherosclerosis (right). Please note that the *tunica intima* is presented here as one layer of endothelial cells covering the acellular matrix, which is incorrect.


Source: By courtesy of *Encyclopaedia Britannica*; reproduced, with permission, from [73].

previous diffusion or 'filtration pressure' models [93,94] that led to their discovery on the co-localization of proteoglycan biglycan (which has a high binding capacity for lipoproteins [95–97]) in distal layers of coronary *tunica intima* [77,78]. However, localization of proteoglycan biglycan in the outer (distal) layers of DIT [77,78] can offer only a partial explanation: biglycan also localized in different tissues of the human body [98] including cancer tissues [99], but tissues other than the outer coronary *tunica intima* do not show pathologic lipid accumulation in regard to biglycan.

Scientists working on mathematical modeling of atherosclerosis [100,101] also favored a filtration pressure model [93] with a constant radially outward flow of plasma into the *tunica intima* caused by arterial blood pressure. In particular, Dr. Fok suggested a model with physical transport of LDL-C from the proximal parts of the intima to the distal parts, followed by washing out from the distal parts by blood; then the LDL-C accumulates near the elastic lamina because of the presence of biglycan and the permeability block by *lamina elastica interna* [102]. Although the models are well-designed, they are incongruent with known patterns of lipid accumulation resulting from the same diffusion pressure and LDL-C invasion in the *tunica intima* of nondiseased human aortas [103].

History of the presumption on lipid invasion from arterial luminal blood into coronary wall and alternative hypotheses
Therefore, the question is: why does atherosclerosis research advocate this self-contradictory model of LDL-C deposition from the

coronary artery lumen to the coronary *tunica intima* if it is in conflict with known observations? There ought to be a reason why coronary atherosclerosis research is so adherent to an obviously contradictory model of disease pathogenesis. I believe that recounting how atherosclerosis research has arrived at this conclusion could help us to resolve this puzzle. Even taking into account early work Rudolph Virchow and Carl von Rokitansky, the credit for this scientific concept should be given to a series of seminal experiments by Anitschkow and Chalatow [104] and further elaborations by Anitschkow [22,105,106]. In his most famous English publication, Anitschkow stated: "Lipids enter the arterial wall as compounds with protein fractions of blood plasma directly from arterial lumen" [107]. Already, at that time, the extrapolations from the rabbit model (no natural cholesterol consumption, no coronary DIT) to human coronary atherosclerosis (cholesterol consumption, coronary artery with significant DIT) was criticized by experts [108,109]. Remarkably, observations of early stages of human coronary atherosclerosis from the same group had already shown initial lipid deposition not in the proximal but in the distal layers of DIT [79], thereby bearing some contradictions to the hypothesis advanced by the authors. In addition, the significance of proliferative morphogenesis in the coronary *tunica intima* forming a diffuse intimal thickening, which Anitschkow had hailed as crucial knowledge for atherosclerosis research [22], was denounced in a later report from this group [110] (the nature of the reasons behind such reversal is beyond the scope of this review).

**FIGURE 6**

During early stages of coronary atherosclerosis, the initial lipid deposition occurs in deep layers of the *tunica intima*, which are separated from the subendothelial region by numerous cell layers and matrix. At the same time, the subendothelial region and the part of the *tunica intima* proximal to the outer endothelium do not show any lipid accumulation. The initial lipid deposition in deep layers of the *tunica intima* occurred immediately above the internal elastic lamina and is not accompanied by macrophage infiltration. Even with further accumulation of lipids in the deep *tunica intima*, lipid deposits never coincide with macrophage infiltration. I indicates the intima and M is the media. (b,e,h,k,n,q) Sudan IV stain. (c,f,i,l,o,r) Immunostaining with anti-CD68 antibody (macrophages). Arrowheads indicate internal elastic lamina. Bars represent 100 μ m. DIT indicates diffuse intimal thickening and PIT is pathologic intimal thickening. Reproduced, with permission, from [77]. This high-resolution image is courtesy of Dr Nakashima.

A validity of the consensus lipid hypothesis of pathogenesis of coronary atherosclerosis has been explicitly challenged in recent times, notably by Stehbens [111–126] and Ravnkov [127–141]. Objections highlighted incoherencies of the accepted view and offered alternative detailed pathogenetic models: hemodynamic stress and aging by Stehbens [142–147] and infection hypothesis with lipoproteins binding with microbes forming aggregates impairing arterial *vasa vasorum* by Ravnkov, this impairment was thought to be aggravated by hyperhomocysteinemia [148], see also [149,150].

The Ravnkov and McCully hypothesis [148] on development of the vulnerable plaque is of special importance because it could also explain puzzling observations of small necrotic damage of the coronary intima, occurring before atherosclerotic alterations; with frequency of such necroses increasing with aging [151]. These findings were reported by Velican and Velican (renowned experts in coronary pathology) [151], and later were attributed to vaso-spasm of the coronary *vasa vasorum* [152]. Although potent *vasa vasorum* contraction is possible (e.g., shown as concentration-dependent to administration of endothelin-1 and other endogenous stimuli) [153,154], the Ravnkov–McCully hypothesis [148] gives a parsimonious explanation for these early intimal necrotic alterations. However, these (and some others) well-thought alternative hypotheses have never been considered by the accepted mainstream opinion as pathogenetic models of the disease, although today's achievements in coronary atherosclerosis therapeutic treatment still are, at best, very modest.

Recently, the accepted view on coronary atherosclerosis pathogenesis has been challenged again by new interpretation (Senef and coauthors) of the disease as the cholesterol sulfate deficiency syndrome, emphasizing increased blood viscosity [155], actually bridging to Ravnkov and McCully hypothesis [148]. It remains to be seen whether this novel hypothesis could alter traditional approaches in selection of therapeutic targets for treatment of coronary atherosclerosis. Nevertheless, the hypothesis regarding lipid invasion from the arterial lumen into the coronary wall was further advanced in a series of publications by Ross and coauthors [156–179] and formulated as ‘the response-to-injury hypothesis’ [160]. This hypothesis was proposed after experiments with de-endothelialization of the iliac artery of *Macaca nemestrina*. This experimental injury resulted in smooth muscle cell (SMC) proliferation and intimal thickening; the authors also suggested that the loss of endothelial integrity facilitated lipid invasion from the lumen into the arterial wall and stimulated SMC migration and proliferation [156]. Interestingly, the initial hypothesis by Ross and coauthors emphasized the proliferation of arterial SMCs in the *tunica intima* as the initiation of the pathology [156–158,180], whereas later analyses put an emphasis on the inflammatory nature of coronary atherosclerosis [174,175,178,179]. Again, although the research mentioned in one publication that the amount of intimal smooth muscle increases with age [159], the series of publications has depicted a normal coronary artery design with the *tunica intima* as a single-cell-layer compartment [159,160,180].

However, because the following studies have shown that endothelial injury is neither necessary nor sufficient for human coronary atherosclerosis initiation (e.g., [181]) and because the subendothelial space is highly accessible to lipoproteins even with intact endothelium [182], the response-to-injury hypothesis was

modified. Williams and Tabas proposed the response-to-retention hypothesis to accommodate new observations [49,183]. This hypothesis proposed the subendothelial retention of atherogenic lipoproteins as the central pathogenic process in atherosclerosis [49,183,184]. Although stress-induced changes in the arterial wall were suggested as important preconditions, subendothelial lipoprotein retention was proposed as an absolute requirement for atherosclerosis initiation, which could take place even in the absence of stress-induced changes in the arterial wall [49,183,184]. The response-to-injury hypothesis continued to be adherent to the view that the human coronary *tunica intima* is a single-cell-layer compartment or is negligible in respect to the number of cell layers compared to *tunica media* [184–186]. Assumptions from this group on the initiation of human coronary atherosclerosis are based on the perception of the coronary *tunica intima* as a single cell layer or as a tissue compartment of insignificant thickness compared to *tunica media*. Notably, this depiction appeared even in the publication by Tabas *et al.*, in which the authors reprinted the microscopic images of coronary arteries from the Nakashima *et al.* publication (Fig. 4) showing that the *tunica intima* is thicker than the *tunica media* [187]. The response-to-injury hypothesis [156–179] and the response-to-retention hypothesis [184–186] assumed that SMCs migrate from media to intima and proliferate, thereby they refute initial intimal cell proliferation as the pathogenesis of the disease.

Another research development supporting lipid invasion from the arterial lumen into the coronary wall was carried out by Hansson and coauthors [188,189]. Although this research was mostly dedicated to pathology related to later events (mature plaque), it undoubtedly supports the pathway of lipoprotein invasion from luminal blood into the coronary wall [58,61]. Again, the perception of this research is that the human coronary *tunica intima* artery is a single-cell-layer compartment [58,61,63,66,190].

Undisputed facts on human coronary morphology and available information on the initial patterns of lipid deposition into the coronary wall

All of the above hypotheses are commonly based on two major notions: (i) the presentation of the coronary *tunica intima* as a thin, single-cell-layer compartment or a compartment with scarce residual cellularity; and (ii) the conjecture of lipid invasion from the luminal site into the coronary artery wall. As we can see, the first notion of coronary atherosclerosis research (the human coronary *tunica intima* is a thin single-cell-layer compartment or a compartment with scarce residual cellularity) contradicts all known facts of human coronary morphology and thereby is purely incorrect. The second notion could appear rational under the once-suggested assumption that the human coronary *tunica intima* is vascularized from the coronary lumen. This hypothesis has proposed the nutrition of the *tunica intima* from a vascular net originating from the arterial lumen [191] (republished as [192]). However, later investigations have attributed the finding of ‘luminal vasculature’ to an inappropriately high pressure of a dye solution injected (ten times higher than normal arterial pressure), for details see [93]. Later investigations either do not confirm luminal vasculature in the human coronary at all or, at best, give it a negligible role in intimal nutrition in normal and pathologic conditions [93,193–196].

It has been thoroughly confirmed today that the normal coronary *tunica intima* is an avascular compartment [197]. All observations showed that the normal human coronary *tunica intima*, evolving from a single-cell-layer after birth to DIT in adults, is always an avascular compartment and remains avascular in normal hearts throughout life. Several studies have investigated this topic thoroughly and concluded that the coronary *tunica intima* receives oxygen and nutrients through diffusion from the arterial lumen and the medial *vasa vasorum* [93,198–202]. The previous suggestion that the luminal vasculature can contribute to coronary *tunica intima* nourishment [191,192] was never confirmed. Therefore, when DIT attains a thickness of several-to-ten cell layers (in humans, at approximately five years) the inner and outer compartments of the *tunica intima* are exposed to various concentrations of blood constituents because diffusion is inversely proportional to the square of the distance (i.e., DIT thickness). When this distance is increased, as happens in adult coronary DIT, it must be assumed that contact of outer (deeper) intimal layers with certain blood constituents would be significantly minimized, if not completely diminished. Therefore, for adult and normal aged-thickened coronary *tunica intima* [22,203,204], the pattern of nutrition by diffusion to the outer (deeper) intimal layers should be assumed similar to that of the arterial media in the Wolinsky and Glagov model, known as the ‘critical depth’ of avascular media or ‘rule 29’ [205]. Therefore, the second notion (lipid invasion from a luminal site into the coronary artery wall) is not coherent either with facts of avascular design of the *tunica intima* or with the patterns of initial lipid deposition at the initiation of human coronary atherosclerosis [77,78,80,81].

Paradoxical patterns of initial lipid deposition in the human coronary artery

The facts are: (i) the initial lipid depositions have begun to appear in human coronary atherosclerosis in a region of the coronary *tunica intima* that is distal to the coronary lumen; (ii) no depositions are observed in regions of the *tunica intima* proximal to the lumen at the same time. Using common sense, such a counterintuitive pattern of initial lipid depositions constitutes a paradox.

Observations that are paradoxical to a hypothesis probably occur in all scientific studies because observations often arrive ahead of knowledge. There are two main ways paradoxical observations can be handled. One way is to supplement the initial hypothesis by conditions under which a paradox could be explained as a logical event. An alternative solution is to offer a new hypothesis in which a paradoxical observation initially appears as a logical event. Both approaches are valid and are commonly used in scientific practice. Both approaches have also been used to explain the paradoxical pattern of initial lipid accumulation in coronary atherosclerosis – complementing the initial hypothesis with new conditions [77,78,101,102] and offering a new hypothesis [206]. However, such logical approaches are extremely rare in analyses of coronary atherosclerosis.

Surprisingly, mainstream analyses of coronary atherosclerosis have chosen to pursue a third approach: presenting the consensus hypotheses grounded on lipid invasion from the arterial lumen while depicting the human coronary *tunica intima* as a thin, single-cell-layer compartment and not mentioning the counterintuitive distal lipid depositions. In such pathogenic models of coronary

atherosclerosis, the paradoxical initial deep lipid depositions are simply omitted. I believe that we should not shrug off paradoxical observations of disease initiation just because they could not be explained by the consensus hypothesis, especially considering our limited achievement in the prevention and cure of coronary atherosclerosis [207,208]. I strongly believe that analysis of paradoxical patterns of the disease initiation could help us think out of the box and reveal obscure mechanisms of disease pathogenesis [206].

Could there be an alternative route for initial lipid depositions into a deep part of coronary tunica intima?

Everything eventually comes to a simple question: if at the initiation of coronary atherosclerosis lipids do not invade the coronary wall from a coronary lumen proper where do they come from? If there is no valid model of lipid invasion from the coronary lumen, is there an alternative route via which lipids can come? Yes, there is. This alternative route of lipid deposition is the vascularization of the coronary *tunica intima* from the adventitial or medial *vasa vasorum*, which has been shown by many studies to contribute to coronary plaque progression and instability (bear in mind that coronary plaques are confined to the coronary *tunica intima*) [200,209–214].

The above plaque vascularization route has been shown by numerous studies and is assumed to be the route from which additional lipoproteins and inflammatory cells invade coronary plaques and surrounding intimal tissues, significantly aggravating pathology (i.e., plaque enlargement, instability and rupture) [209,214–222]. These newly formed vessels originated from the adventitial/medial *vasa vasorum* [209,214,216–225]. However, the above research stops short from suggesting the adventitial/medial *vasa vasorum* route as the source of lipid depositions as initiation of coronary atherosclerosis. Moreno *et al.* suggested the following hypothesis: “Adventitial-derived *vasa vasorum* neovascularization develops under the trigger of oxidized low-density lipoprotein deposits in the intima, mediated by hypoxia and Toll-like receptors” [200], obviously designating intimal neovascularization as the event induced by pre-existed lipoprotein depositions.

Therefore, if the above route, which is the alternative route to lipid cell invasion from the coronary lumen, is undoubtedly confirmed to contribute to advanced atherosclerotic pathological formations in the coronary *tunica intima*, the inevitable question is: could the same vascular route cause not only progression but also the initiation of the disease? This question receives a positive answer: yes, this route is very credible for the initiation of lipid depositions. There are numerous observations showing that neovascularization of the coronary *tunica intima* from the adventitial *vasa vasorum* occurs under a variety of conditions before the occurrence of any pathologic features in the coronary artery [93,94,196,197,199–201,226–230].

This neovascularization extends from the *tunica media* vasculature, penetrates the internal elastic lamina and forms a capillary net in the deep layers of the coronary *tunica intima* [227,231]. This intimal neovascularization pattern of the *tunica intima* is common for all arterial DITs that begin to evolve into diseased conditions [226,229]. Adding these facts to the paradoxical initial lipid deposition in deep distal layers of the *tunica intima* (where there is no initial lipid deposition in layers proximal to the coronary lumen) has turned the paradoxical initial lipid distribution into a logical event.

Why does the coronary tunica intima become vascularized?

But why does the coronary *tunica intima* become vascularized in the absence of any visible histopathologic alteration? What events in the coronary wall would promote this morphogenesis? It is well known that coronary atherosclerosis is an aging-related disease [232–234]. After the coronary *tunica intima* differentiates from a single-cell-layer compartment (after birth design) to a multi-layered adult *tunica intima* (adult design) this compartment remains avascular, receiving sufficient oxygen and nutrients through diffusion from the arterial lumen and the adventitial *vasa vasorum*, terminating in two-thirds of the *tunica media* [93,199–202].

However, the cells of the *tunica intima* remain the most replicating cell population in the arterial conduit including in the coronary wall [235]. It has been long known that excessive cell proliferation in coronary *tunica intima* can be triggered by a variety of diverse nonspecific signals. Friedman writes: "...an artery responds to almost any sort of physical or chemical injury to which it may have been exposed with a hyperplasia or replication of its surviving or still-intact remnants. Thus, whether the injury is induced by transplantation, by needle puncture, by freezing, by heat, by exposure to electron radiation, by induced hypertension, by cholesterol infiltration, or by pressor amines, the typical response on the tunic affected is a hyperplastic one" [236].

It has been confirmed by many studies that the coronary *tunica intima* (i.e., DIT) gets thicker with aging, along with the *tunica intima* of other large elastic arteries [203,237,238] and can transition from DIT to pre-PIT. However, whereas DIT occurs mostly evenly in the coronary circumference [21], pre-PIT lacks regularity and in some areas the *tunica intima* becomes initially enlarged more than in others [239,240].

What happens when the coronary *tunica intima* becomes larger owing to cell proliferation? A straightforward answer was given by Osborn: "When the intima of the coronary artery exceeds a certain thickness parts must either die or develop secondary blood supply" [241]. Because tissue hypoxia is a known inducer of angiogenesis and neovascularization [242–244], neovascularization of the hypoxic deep compartment of the enlarged coronary DIT from the adventitial/medial *vasa vasorum* must follow coronary DIT expansion. Therefore, the only logical deduction from the above facts is that intimal proliferation and/or thickening causing neovascularization as a result of hypoxia of deep layers of the *tunica intima* opens a door for a direct lipid extraction from the leaky neovasculature [242,243,245–247] by components of deep layers of the *tunica intima* (i.e., by biglycan).

Because the biglycan in the deep *tunica intima* of the normal adult human coronary is always separated from blood flow by many cell or matrix layers, it is never exposed to certain blood constituents, and it is likely that blood lipoproteins are never in contact with the deep compartment. In this sense, matrix components of the deep layers of the coronary *tunica intima* can acquire some properties of privileged tissue (high affinity to LDL-C) by differentiating in a special environment, similar to the immunologic privileges defined by developmental anatomy [248,249]. As soon as newly formed capillary nets penetrate into deep layers of the coronary *tunica intima*, which never were in contact with free blood-flow before, biglycan (and possibly other matrix components that evolved in such an avascular environment) starts to bind lipoproteins and extracts them from the blood.

New pathogenetic model of the initiation of coronary atherosclerosis


This pathogenetic model of the initiation of coronary atherosclerosis, which incorporates all facts (real morphologic design of human epicardial coronary arteries, paradoxical patterns of lipid deposition caused by preceding neovascularization of deep layers of coronary *tunica intima*), was detailed in an early publication [206] and is depicted here in Fig. 7. The above hypothesis also explains why there is always a fibrous cap on top of a plaque [83,213,250–252] – because plaques are always initiated under fibromuscular *tunica intima*.

Suggested mechanism of the initiation of lipid deposition is not unique to coronary atherosclerosis

The suggested mechanism of the initiation of lipid deposition pathology is not unique. An identical mechanism, involving neovascularization of a normally avascular tissue compartment, followed by lipoprotein deposition, is well known for corneal lipid keratopathy. The central cornea is normally an avascular compartment [253–255]. More than 50 years ago, Cogan and Kuwabara described cornea lipid keratopathy, consisting of lipid deposition in the corneal *substancia propria* followed by fatty plaque formation, as occurring only in corneal areas that have been previously neovascularized [256]. The authors also pointed to morphologic similarities between cornea lipid plaques and those in atherosclerosis and suggested common pathogenesis [256]. In the following years, numerous reports reaffirmed a causal role for neovascularization in corneal lipid deposition and, hence, the main treatment modality has become the inhibition of neovascularization [253,254,257–269]. It was also noted that the contribution of inflammation to this pathogenesis is limited to the induction of angiogenesis [264]. Lipoprotein levels of the aqueous humor are thought to be close to those of blood [270–275]. It is important to note that, although the corneal *substancia propria* is separated from the aqueous humor only by a single-cell-layer of Descemet epithelium, lipid depositions were never (or extremely rarely [276]) observed before corneal neovascularization. Interestingly, another member of the proteoglycan family, a small, leucine-rich lumican, which has a vital role in embryonic development and tissue repair, is also predominantly expressed in the adult cornea and in cells of thickened coronary intima [277]. Lumican has also been implicated in lipid retention in atherosclerosis [278]. These facts strongly favor the model of direct lipid extraction from the permeable neovasculature into the cornea proper rather than a diffusion model. The fact that a similar sequence of events underlies the pathogenesis of the completely unrelated corneal disease, in terms of neovascularization and lipid deposition, reinforces the suggested new hypothesis on the mechanisms of coronary atherosclerosis [206].

Logic of scientific hypotheses

Facts showed that lipoprotein accumulation in coronary *tunica intima* is not the initiation of coronary atherosclerosis but is a consequence of enlarged intimal thickness, cell hypoxia and intimal neovascularization. I completely agree with Geiringer's assertion that "... intimal vascularization is a function of intimal thickness and not of atherosclerosis" [93]. Furthermore, enlarged intimal hyperplasia, or pre-PIT (i.e., cell proliferation in *tunica intima*), is the cause of coronary atherosclerosis.



Drug Discovery Today

FIGURE 7

Schematic representations of the mechanism of coronary atherosclerosis. **(a)** Normal coronary artery. The coronary tunica intima forms diffuse intimal thickening (DIT) with biglycan accumulations in the outer DIT, which is most distant from the arterial lumen. **(b)** DIT enlarged by cell proliferation forming pre-pathologic intimal thickening (pre-PIT). Cells in the outer pre-PIT underwent hypoxia caused by increased diffusion distance. **(c)** Neovascularization of the outer pre-PIT from the adventitial vasa vasorum. Newly formed vessels are highly permeable. **(d)** Biglycan of the outer pre-PIT comes into direct contact with blood low-density lipoprotein cholesterol (LDL-C), which facilitates binding, retention and deposition of LDL-C in the outer PIT, whereas the inner part of PIT is free from lipoproteins. This schematic stage (d) corresponds to fatty streak Grade 1 and Grade 2 in the Nakashima *et al.* study [62].

The current consensus hypothesis on the causation of coronary atherosclerosis (where high levels of LDL-C is the major culprit) is almost unanimously accepted, with only rarely a new hypothesis challenge [155]. The consensus hypothesis has completely superseded an earlier viewpoint that coronary atherosclerosis is initiated by proliferative intimal morphogenesis [279–281]. However, given tremendous effectiveness of current lipid-lowering therapies, how can we explain their inability to eradicate even a majority of cardiovascular events [207]? Coronary atherosclerosis is the major cause of cardiovascular events. How can we explain coronary atherosclerosis in subjects with normal cholesterol levels [282], and even in vegetarians [283,284]? It appears that the scientific and medical communities are focusing on and emphasizing biomarkers that can predict risk, without proof that these biomarkers cause the risk [63,285].

Mechanisms of diseases constitute a fast-developing, state-of-the-art scientific field, which often stretches beyond the scope of established medical concepts. Although well recognized in the past, medical concepts are not always proved to be correct; the author believes that a newer hypothesis should not contradict established concepts that have been proven to be correct so far without good reasoning. Although thoughts on a cause responsible for a phenomenon date back to Aristotle's time, applicability of the thesis to diseases was formulated by the founder of the experimental medicine Claude Bernard: "Indeed, proof that a given condition always precedes or accompanies a phenomenon does not warrant concluding with certainty that a given condition is the immediate cause of that phenomenon. It must still be established that when this condition is removed, the phenomenon will no longer appear..." [286].

It is well known that multiple factors participate during disease development, and can affect the progression and severity of disease. However, we have to choose one or just a few factors that are probably causative and potentially can constitute the therapeutic targets. Therefore, only through distinguishing the cause from all contributing factors can an effective therapeutic target be identified and a cure, leading to disease eradication, be achieved.

In modern medicine this thesis was formulated by William Stehbens: "...differentiating between cause and non-causative factors is essential. Elimination of the latter only ameliorates or reduces the incidence whereas elimination of the former eradicates the disease. Swamps are not a cause of malaria. Draining swamps may reduce the incidence of malaria but it is eradication of the malarial parasites that eliminates the disease. Reduction in incidence rather than elimination of the disease precludes a causal relationship" [287]. The notion on refutability of the consensus hypothesis on pathogenesis of coronary atherosclerosis was directly addressed by Uffe Ravnskov [134]. In this light, facts that coronary atherosclerosis occurs in subjects with normal cholesterol levels [282], even in vegetarians [283,284], and lowering LDL-C levels does not prevent cardiac events in the majority of those at risk of a cardiovascular event [207] contradicts the causative role of LDL-C.

Concluding remarks

Although this review suggested that the uncontrollable cell proliferation in coronary *tunica intima*, followed by neovascularization, is the initiation of coronary atherosclerosis and a potential therapeutic target, the analysis intends only to outline practical

implementation of this suggestion. Although growing evidence suggests that targeting the hypoxia pathway and intimal neovascularization has a great therapeutic potential [288–290], even with this achievement the presence of an enlarged hypoxic intimal compartment in the coronary artery would still persist, inducing neovascularization. The latter brings us back to the Osborn notion: "When the intima of the coronary artery exceeds a certain thickness parts must either die or develop secondary blood supply" [241]. In regard to inhibition of intimal neovascularization, this review also perceives obvious concerns about antiangiogenesis therapy in subjects with an already jeopardized myocardial blood supply. However, even if very local antiangiogenesis actions become available, another side of such actions should be considered.

It was suggested a long time ago by Groszek and Grundy that the intimal neovasculature could be the route by which lipoprotein depositions can be extracted from coronary *tunica intima* [94]. It is worth to recall again that "... intimal vascularization is a function of intimal thickness and not of atherosclerosis" [93]. This review suggests that, if coronary pathologic intimal thickening and initial lipoprotein depositions are diagnosed at early stages of coronary atherosclerosis (Grade 1–2 fatty streaks, Grade 3 PIT), the disease could be reversible. If further cell proliferation and expansion of coronary *tunica intima* are prevented at a stage when lipoprotein depositions still reside in viable coronary tissues, before forming a solid lipid compartment, neovascularization of coronary *tunica intima* is a potentially crucial route for lipoprotein removal and disease reversal [94]. The implementation of the suggestions above is an extremely difficult task but, unless we start to work toward this goal, our research and therapeutic efforts will probably be off-target.

Finally, this review rests with the conclusion that uncontrolled cell proliferation in *tunica intima* of human coronary arteries is the initiation of the coronary atherosclerosis. Obviously, until an enlarged coronary DIT compartment (i.e., pre-PIT) persists, it continues causing hypoxia-inducing angiogenesis and neovascularization of deep layers of coronary *tunica intima* and lipid extraction or deposition. Logically, uncontrolled cell proliferation in coronary *tunica intima* is a cause of coronary atherosclerosis and constitutes a therapeutic target. But is a coronary atherosclerosis the only coronary disease in which intimal cell proliferation could be implicated as the initiation of pathology? Of course not – I have already mentioned that my attention to coronary atherosclerosis was determined by its status as the number one killer in the Western world. Of course, there are other coronary artery pathologies in which cell proliferation in the *tunica intima* is unanimously recognized as the major morphogenetic event. In the future we will analyze coronary pathologies that are completely unrelated to coronary atherosclerosis yet bear the same initiation hallmark – cell proliferation in the coronary *tunica intima*.

Conflicts of interest

The author has no conflict of interest to declare.

Acknowledgments

This review is dedicated to the memory of the renowned zoologist and my dear friend Rostislav A. Shilo (Ростислав Александрович Шило), October 1940 - April 2016, who introduced me to another

world – the world of his zoo. I am lucky to be part of this world and the zoo has changed my life. Rostislav Shilo was Director (and creator) of Novosibirsk Zoo, Russia, which specializes in breeding endangered species for conservation.

References

- 1 Prinz, F. *et al.* (2011) Believe it or not: how much can we rely on published data on potential drug targets? *Nat. Rev. Drug Discov.* 10, 712–712
- 2 Kinch, M.S. *et al.* (2016) An analysis of FDA-approved drugs for cardiovascular diseases. *Drug Discov. Today* 21, 1–4
- 3 Arrowsmith, J. (2011) Trial watch: Phase II failures: 2008–2010. *Nat. Rev. Drug Discov.* 10, 328–329
- 4 Mignani, S. *et al.* (2016) Compound high-quality criteria: a new vision to guide the development of drugs, current situation. *Drug Discov. Today* 21, 573–584
- 5 Raoof, A.A. and Aerssens, J. (2015) Patient-centered drug discovery as the means to improved R&D productivity. *Drug Discov. Today* 20, 1044–1048
- 6 Stary, H.C. *et al.* (1992) A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 85, 391–405
- 7 Miller, H. *et al.* (2005) Modulation of estrogen signaling by the novel interaction of heat shock protein 27, a biomarker for atherosclerosis, and estrogen receptor beta: mechanistic insight into the vascular effects of estrogens. *Arterioscler. Thromb. Vasc. Biol.* 25, e10–e14
- 8 O'Brien, E.R. *et al.* (1996) Beta ig-h3, a transforming growth factor-beta-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions. *Arterioscler. Thromb. Vasc. Biol.* 16, 576–584
- 9 Garvin, M.R. *et al.* (1997) Arterial expression of the plasminogen activator system early after cardiac transplantation. *Cardiovasc. Res.* 35, 241–249
- 10 Angelini, A. *et al.* (1990) Coronary arterial wall and atherosclerosis in youth (1–20 years): a histologic study in a northern Italian population. *Int. J. Cardiol.* 28, 361–370
- 11 Schwartz, S.M. *et al.* (1995) The intima. Soil for atherosclerosis and restenosis. *Circ. Res.* 77, 445–465
- 12 Milei, J. *et al.* (2010) Coronary intimal thickening in newborn babies and ≤1-year-old infants. *Angiology* 61, 350–356
- 13 Cizek, S.M. *et al.* (2007) Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia. *Cardiovasc. Pathol.* 16, 344–350
- 14 Thoma, R. (1883) Ueber die Abhängigkeit der Bindegewebsneubildung in der Arterienintima von den mechanischen Bedingungen des Blutumlaufes. Erste Mittheilung. Die Rückwirkung des Verschlusses der Nabelarterien und des arteriösen Ganges auf die Structur der Aortenwand. *Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin* 93, 443–505 (in German)
- 15 Thoma, R. (1886) Ueber die Abhängigkeit der Bindegewebsneubildung in der Arterienintima von den mechanischen Bedingungen des Blutumlaufes. *Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin* 105, 1–28 (in German)
- 16 Thoma, R. (1921) Über die Intima der Arterien. *Virchows Archiv* 230, 1–45 (in German)
- 17 Thoma, R. (1923) Über die Genese und die Lokalisationen der Arteriosklerose. *Virchows Archiv* 245, 78–122 (in German)
- 18 Thoma, R. and Kaefer, N. (1889) Ueber die Elasticität gesunder und kranker Arterien. *Virchows Archiv* 116, 1–27 (in German)
- 19 Subbotin, V.M. (2007) Analysis of arterial intimal hyperplasia: review and hypothesis. *Theor. Biol. Med. Model.* 4, 41
- 20 Wolkoff, K. (1923) Über die histologische Struktur der Coronararterien des menschlichen Herzens. *Virchows Archiv* 241, 42–58 (in German)
- 21 Nakashima, Y. *et al.* (2002) Distributions of diffuse intimal thickening in human arteries: preferential expression in atherosclerosis-prone arteries from an early age. *Virchows Archiv* 441, 279–288
- 22 Anitschkow, N. (1933) Experimental arteriosclerosis in animals. In *Arteriosclerosis: A Survey of the Problem* (Cowdry, E.V., ed.), pp. 271–322, Macmillan
- 23 Wolkoff, K. (1924) Über die Altersveränderungen der Arterien bei Tieren. *Virchows Archiv* 252, 208–228 (in German)
- 24 Robertson, J.H. (1960) The significance of intimal thickening in the arteries of the newborn. *Arch. Dis. Child.* 35, 588–590
- 25 French, J.E. *et al.* (1963) Intimal changes in the arteries of ageing swine. *Proc. R. Soc. B Biol. Sci.* 158, 24–42
- 26 French, J.E. (1966) Atherosclerosis in relation to the structure and function of the arterial intima, with special reference to the endothelium. *Int. Rev. Exp. Pathol.* 5, 253–353
- 27 French, J. (1971) The Structure of Arteries, Growth Adaptation and Repair: The Dilemma of Normal. In *Advances In Experimental Medicine And Biology, The Artery and the Process of Arteriosclerosis*, (vol. 16a) (Wolf, S., ed.), pp. 1–51, Springer, US
- 28 Velican, C. and Velican, D. (1975) Coronary arteries in infants up to the age of ten years. I. Chronology of adaptive intimal changes. *Rev. Roum. Med. Intern.* 13, 19–24
- 29 Velican, C. and Velican, D. (1976) Coronary arteries in children up to the age of ten years II. Intimal thickening and its role in atherosclerotic involvement. *Med. Intern.* 14, 17–24
- 30 Velican, C. and Velican, D. (1978) Particular aspects of the children coronary artery remodelling. *Med. Intern.* 16, 127–134
- 31 Velican, C. and Velican, D. (1979) Some particular aspects of the microarchitecture of human coronary arteries. *Atherosclerosis* 33, 191–200
- 32 Velican, C. and Velican, D. (1980) The precursors of coronary atherosclerotic plaques in subjects up to 40 years old. *Atherosclerosis* 37, 33–46
- 33 Velican, D. and Velican, C. (1980) Atherosclerotic involvement of the coronary arteries of adolescents and young adults. *Atherosclerosis* 36, 449–460
- 34 Velican, C. and Velican, D. (1983) The neglected coronary atherosclerosis. *Atherosclerosis* 47, 215–229
- 35 Velican, C. and Velican, D. (1983) Progression of coronary atherosclerosis from adolescents to mature adults. *Atherosclerosis* 47, 131–144
- 36 Velican, C. and Velican, D. (1985) Study of coronary intimal thickening. *Atherosclerosis* 56, 331–344
- 37 Velican, C. *et al.* (1985) Intimal thickening and atherosclerotic involvement of the left main coronary artery. *Med. Intern.* 23, 95–101
- 38 Velican, D. *et al.* (1987) Prevalence of the “normal” aspect of the coronary arteries in an unselected population sample of Bucharest aged 1–60 years. *Med. Intern.* 25, 113–119
- 39 Velican, C. and Velican, D. (1988) Coronary atherosclerosis: where are we now? *Med. Intern.* 26, 5–13
- 40 Velican, D. and Velican, C. (1989) Coronary anatomy and microarchitecture as related to coronary atherosclerotic involvement. *Med. Intern.* 27, 257–262
- 41 Bohorquez, F. and Stout, C. (1972) Arteriosclerosis in exotic mammals. *Atherosclerosis* 16, 225–231
- 42 Bálint, A. (1974) The fine structure of the mammalian arterial wall. In *Arterial Lesion and Arteriosclerosis* (Jellinek, H., ed.), Plenum Press
- 43 Ward, B.C. and Shively, J.N. (1974) Atherosclerosis in rat kangaroos. *Arch. Pathol.* 98, 90–93
- 44 Hirvonen, J. *et al.* (1985) Coronary intimal thickenings and lipids in Finnish children who died violently. *Acta Paediatr. Scand. Suppl.* 318, 221–224
- 45 Sims, F.H. *et al.* (1989) The intima of human coronary arteries. *Am. Heart J.* 118, 32–38
- 46 Cucu, F. (1986) Coronary intima: the phylogenetic approach to appearance of lesions. *Med. Intern.* 24, 163–169
- 47 Cucu, F. (1980) Phylogenetic evolution of the coronary artery intima and its relevance to atherosclerotic involvement. *Med. Intern.* 18, 99–104
- 48 Berry, C. (1989) Organogenesis of the arterial wall. In *Diseases of the Arterial Wall*, pp. 55–70, Springer
- 49 Williams, K.J. and Tabas, I. (1995) The response-to-retention hypothesis of early atherogenesis. *Arterioscler. Thromb. Vasc. Biol.* 15, 551–561
- 50 Conisny, P.M. (1995) Pathogenesis of atherosclerosis. *Am. J. Roentgenol.* 164, 553–558
- 51 Allen, S. (1998) Lipid vascular wall interaction. *Curr. Opin. Cardiol.* 13, 439–446
- 52 Lusis, A.J. (2000) Atherosclerosis. *Nature* 407, 233–241
- 53 Dzau, V.J. *et al.* (2002) Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. *Nat. Med.* 8, 1249–1256
- 54 DiCorleto, P.E. and Gimbrone, M.A.J. (1996) Vascular endothelium. In *Atherosclerosis and Coronary Artery Disease* (Fuster, V. *et al.* eds), pp. 387–399, Lippincott-Raven
- 55 Junqueira, L. *et al.* (1998) *Basic Histology* (9th edn). Appleton & Lange, Stamford, Conn
- 56 Dellmann, H.D., ed. (1998) *Textbook of Veterinary Histology*, Lippincott Williams & Wilkins
- 57 Sternberg, S.S., ed. (1997) *Histology for Pathologists*, Lippincott-Raven

- 58 Hansson, G.K. (2005) Inflammation, atherosclerosis, and coronary artery disease. *N. Engl. J. Med.* 352, 1685–1695
- 59 Napoli, C. *et al.* (2006) Rethinking primary prevention of atherosclerosis-related diseases. *Circulation* 114, 2517–2527
- 60 Rader, D.J. and Daugherty, A. (2008) Translating molecular discoveries into new therapies for atherosclerosis. *Nature* 451, 904–913
- 61 Hansson, G.K. and Hermansson, A. (2011) The immune system in atherosclerosis. *Nat. Immunol.* 12, 204–212
- 62 Weber, C. and Noels, H. (2011) Atherosclerosis: current pathogenesis and therapeutic options. *Nat. Med.* 17, 1410–1422
- 63 Libby, P. *et al.* (2011) Progress and challenges in translating the biology of atherosclerosis. *Nature* 473, 317–325
- 64 Little, P.J. *et al.* (2011) Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. *Pharmacol. Ther.* 131, 255–268
- 65 van der Valk, F.M. *et al.* (2012) Novel anti-inflammatory strategies in atherosclerosis. *Curr. Opin. Lipidol.* 23, 532–539
- 66 Swirski, F.K. *et al.* (2012) The ins and outs of inflammatory cells in atheroma. *Cell Metab.* 15, 135–136
- 67 Schober, A. and Siess, W. (2012) Lysophosphatidic acid in atherosclerotic diseases. *Br. J. Pharmacol.* 167, 465–482
- 68 Rhee, J.W. and Wu, J.C. (2013) Advances in nanotechnology for the management of coronary artery disease. *Trends Cardiovasc. Med.* 23, 39–45
- 69 Ammirati, E. *et al.* (2015) The role of T and B cells in human atherosclerosis and atherothrombosis. *Clin. Exp. Immunol.* 179, 173–187
- 70 George, S.J. and Johnson, J., (eds) (2010) *Atherosclerosis: Molecular and Cellular Mechanisms*, Blackwell Science
- 71 McPherson, J.A. *et al.* (2011) Coronary artery atherosclerosis. *Medscape* Available at: <http://emedicine.medscape.com/article/153647-overview>
- 72 Willyard, C. (2013) Pathology: at the heart of the problem. *Nature* 493, S10–S11
- 73 Britannica Online Encyclopaedia (2015) *Atherosclerosis* <http://www.britannica.com/science/atherosclerosis>
- 74 Willerson, J.T. and Holmes, Jr., D.R. (eds.), (2015) *Coronary Artery Disease*, Springer
- 75 Madjid, M. and Willerson, J.T. (2015) Clinical use of serum biomarkers in the prediction of cardiovascular risk. In *Coronary Artery Disease* (Willerson, J.T. and Holmes, Jr., D.R. (eds.), pp. 21–38, Springer. Chapter 2
- 76 Martínez-González, B. *et al.* (2015) Morphological analysis of major segments of coronary artery occlusion. Importance in myocardial revascularization surgery. *Int. J. Morphol.* 33, 1205–1212
- 77 Nakashima, Y. *et al.* (2007) Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. *Arterioscler. Thromb. Vasc. Biol.* 27, 1159–1165
- 78 Nakashima, Y. *et al.* (2008) Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. *Cardiovasc. Res.* 79, 14–23
- 79 Wolkoff, K. (1929) Über die Atherosklerose der Coronararterien des Herzens. *Beiträge zur Pathologischen Anatomie und zur Allgemeinen Pathologie* 82, 555–596 (in German)
- 80 Nakashima, T. and Tashiro, T. (1968) Early morphologic stage of human coronary atherosclerosis. *Kurume. Med. J.* 15, 235–242
- 81 Fukuchi, M. *et al.* (2002) Normal and oxidized low density lipoproteins accumulate deep in physiologically thickened intima of human coronary arteries. *Lab. Invest.* 82, 1437–1447
- 82 Available at: <http://www.merriam-webster.com/dictionary/pathogenesis#medicalDictionary>
- 83 Burke, A.P. *et al.* (1997) Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. *N. Engl. J. Med.* 336, 1276–1282
- 84 Stary, H.C., ed. (1999) *Atlas of Atherosclerosis Progression and Regression*, Parthenon Pub. Group
- 85 Kolodgie, F.D. *et al.* (2004) Pathologic assessment of the vulnerable human coronary plaque. *Heart* 90, 1385–1391
- 86 Shanmugam, N. *et al.* (2010) Atherosclerotic plaque regression: fact or fiction? *Cardiovasc. Drugs Ther.* 24, 311–317
- 87 National Institutes of Health (1985) Consensus development summaries. Lowering blood cholesterol to prevent heart disease. *Conn. Med.* 49, 357–364
- 88 National Institutes of Health (1985) Lowering blood cholesterol to prevent heart disease. *Natl. Inst. Health Consens. Dev. Conf. Consens. Statement* 5, 27
- 89 Consensus Conference (1985) Lowering blood cholesterol to prevent heart disease. *JAMA* 253, 2080–2086
- 90 Ernst, N.D. (1985) NIH Consensus Development Conference on lowering blood cholesterol to prevent heart disease: implications for dietitians. *J. Am. Diet. Assoc.* 85, 586–588
- 91 NIH Consensus Development Conference (1985) Lowering blood cholesterol to prevent heart disease. *Wis. Med. J.* 84, 18–19
- 92 Malone, P.C. and Agutter, P.S. (2016) Deep venous thrombosis: the valve cusp hypoxia thesis and its incompatibility with modern orthodoxy. *Med. Hypotheses* 86, 60–66
- 93 Geiringer, E. (1951) Intimal vascularization and atherosclerosis. *J. Pathol. Bacteriol.* 63, 201–211
- 94 Groszek, E. and Grundy, S.M. (1980) The possible role of the arterial microcirculation in the pathogenesis of atherosclerosis. *J. Chronic Dis.* 33, 679–684
- 95 Olin, K.L. *et al.* (1999) Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells. *J. Biol. Chem.* 274, 34629–34636
- 96 Olin-Lewis, K. *et al.* (2002) ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. *J. Lipid Res.* 43, 1969–1977
- 97 O'Brien, K.D. *et al.* (2004) Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. *Atherosclerosis* 177, 29–35
- 98 Hogemann, B. *et al.* (1997) Expression of biglycan, decorin and proteoglycan-100/CSF-1 in normal and fibrotic human liver. *Pathol. Res. Pract.* 193, 747–751
- 99 Aprile, G. *et al.* (2013) Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. *Tumour Biol.* 34, 131–137
- 100 Bratzler, R.L. *et al.* (1977) Theoretical models for transport of low-density lipoproteins in the arterial wall. *Adv. Exp. Med. Biol.* 82, 943–951
- 101 Fok, P.W. (2012) Mathematical model of intimal thickening in atherosclerosis: vessel stenosis as a free boundary problem. *J. Theor. Biol.* 314, 23–33
- 102 Fok, P.W. Personal communication (2013)
- 103 Torzewski, M. *et al.* (2009) Investigation of Sudan IV staining areas in aortas of infants and children: possible prelesional stages of atherogenesis. *Atherosclerosis* 206, 159–167
- 104 Anitschkow, N. and Chalatow, S. (1913) Ueber experimentelle Cholesterinstearose und ihre Bedeutung fuer die Entstehung einiger Pathologischer Prozesse. *Zentralbl Allg Pathol Pathol Anat* 24, 1–9 (in German)
- 105 Anitschkow, N. (1924) Zur Ätiologie der Atherosklerose. *Virchows Archiv* 249, 73–82 (in German)
- 106 Anitschkow, N. (1915) Über die experimentelle Atherosklerose der Herzkappen. *Virchows Archiv* 220, 233–256 (in German)
- 107 Anitschkow, N.N. (1967) A history of experimentation on arterial atherosclerosis in animals. In *Cowdry's Arteriosclerosis: A Survey of the Problem* (Blumenthal, H.T., ed.), pp. 22–44, Thomas
- 108 Beitzke, H. (1928) Zur entstehung der atherosklerose. *Virchows Archiv* 267, 625–647 (in German)
- 109 Duff, G.L. (1935) Experimental cholesterol arteriosclerosis and its relationship to human arteriosclerosis. *Arch. Pathol.* 20 (81–123), 259–304
- 110 Volkova, K.G. (1952) Critical considerations on Moshkovich's article "Hyperplastic arteriosclerosis or atherosclerosis". *Arkhiv Patologii* 14, 88
- 111 Stehbens, W.E. (1975) The role of lipid in the pathogenesis of atherosclerosis. *Lancet* 305, 724–727
- 112 Stehbens, W.E. (1975) Lipid in atherosclerosis. *Lancet* 2, 29–30
- 113 Stehbens, W.E. (1988) Cholesterol feeding and experimental atherosclerosis. *Atherosclerosis* 73, 85–86
- 114 Stehbens, W.E. (1988) Flaws in the lipid hypothesis of atherogenesis. *Pathology* 20, 395–396
- 115 Stehbens, W.E. (1989) The lipid hypothesis. *Med. J. Aust.* 150, 108
- 116 Stehbens, W.E. (1990) Hypercholesterolemia and atherogenesis. *Can. Med. Assoc. J.* 142, 799–801
- 117 (1991) *The controversial role of blood cholesterol. Is it really atherogenic?*, Proceedings of the XXIII International Dairy Congress, Montreal, October 8–12, 1990, Vol. 2. pp. 1119–1130 ISBN:0-9694713-0-0
- 118 Stehbens, W.E. (1993) Diet, cholesterol and heart-disease – epidemiologic illusion or delusion. *Stress Med.* 9, 153–158
- 119 Stehbens, W.E. (1997) The pathogenesis of atherosclerosis: a critical evaluation of the evidence. *Cardiovasc. Pathol.* 6, 123–153
- 120 Stehbens, W.E. (1999) Anitschkow and the cholesterol over-fed rabbit. *Cardiovasc. Pathol.* 8, 177–178
- 121 Stehbens, W.E. (2001) Coronary heart disease, hypercholesterolemia, and atherosclerosis II. Misrepresented data. *Exp. Mol. Pathol.* 70, 120–139
- 122 Stehbens, W.E. (2001) Coronary heart disease, hypercholesterolemia, and atherosclerosis I. False premises. *Exp. Mol. Pathol.* 70, 103–119
- 123 Stehbens, W.E. (2002) Relevance of hypercholesterolemia to fetal and pediatric atherosclerosis. *Pediatr. Pathol. Mol. Med.* 21, 259–278

- 124 Stehbens, M.D.P.W.E. (1997) The pathogenesis of atherosclerosis: a critical evaluation of the evidence. *Cardiovasc. Pathol.* 6, 123–153
- 125 Stehbens, W.E. (1975) The role of lipid in the pathogenesis of atherosclerosis. *Lancet* 1, 724–727
- 126 Stehbens, W.E. (2002) Relevance of hypercholesterolemia to fetal and pediatric atherosclerosis. *Pediatr. Pathol. Mol. Med.* 21, 259–278
- 127 Ravnskov, U. and McCully, K.S. (2012) Infections may be causal in the pathogenesis of atherosclerosis. *Am. J. Med. Sci.* 344, 391–394
- 128 Ravnskov, U. et al. (2012) No scientific support for linking dietary saturated fat to CHD. *Br. J. Nutr.* 107, 455–457
- 129 Ravnskov, U. (2012) More discrepancies around saturated fat and cardiovascular diseases. *Nutrition* 28, 713
- 130 Ravnskov, U. (2011) The doubtful association between blood lipid changes and progression of atherosclerosis. *Int. J. Cardiol.* 153, 95
- 131 Ravnskov, U. (2008) Hypercholesterolaemia – should medical science ignore the past? *BMJ* 337, 1681
- 132 Ravnskov, U. (2007) Lack of evidence for recommended low-density lipoprotein cholesterol treatment targets. *Annal. Int. Med.* 146, 614
- 133 Ravnskov, U. and Sutter, M.C. (2004) Aggressive lipid-lowering therapy and regression of coronary atheroma. *JAMA* 292, 38
- 134 Ravnskov, U. (2004) Karl Popper and the cholesterol hypothesis. *Tidsskr. Nor. Lægeforen.* 124 (2517), (in Norwegian)
- 135 Ravnskov, U. et al. (2002) Studies of dietary fat and heart disease. *Science* 295, 1464–1466
- 136 Ravnskov, U. (2002) Diet-heart disease hypothesis is wishful thinking. *BMJ* 324, 238
- 137 Ravnskov, U. (2002) Is atherosclerosis caused by high cholesterol? *QJM* 95, 397–403
- 138 Ravnskov, U. (2002) A hypothesis out-of-date: the diet-heart idea. *J. Clin. Epidemiol.* 55, 1057–1063
- 139 Ravnskov, U. (1998) The questionable role of saturated and polyunsaturated fatty acids in cardiovascular disease. *J. Clin. Epidemiol.* 51, 443–460
- 140 Ravnskov, U. (1990) Lowering cholesterol concentrations and mortality. *BMJ* 301, 814
- 141 Ravnskov, U. (1991) An elevated serum cholesterol level is secondary, not causal, in coronary heart disease. *Med. Hypotheses* 36, 238–241
- 142 Stehbens, W.E. (1975) Role of hemodynamics in pathogenesis of atherosclerosis. *Prog. Cardiovasc. Dis.* 18, 89–103
- 143 Stehbens, W.E. (1982) Hemodynamics and atherosclerosis. *Biorheology* 19, 95–101
- 144 Stehbens, W.E. et al. (1990) Hemodynamic induction of atherosclerosis – localization, morphology and biochemistry. *Monogr. Atheroscler.* 15, 1–12
- 145 Stehbens, W.E. (2000) Epidemiological risk factors of coronary heart disease are not causal in atherosclerosis. *Clin. Exp. Hypertens.* 22, 445–453
- 146 Stehbens, W.E. (1975) The role of hemodynamics in the pathogenesis of atherosclerosis. *Prog. Cardiovasc. Dis.* 18, 89–103
- 147 Stehbens, W.E. (1995) Atherosclerosis and degenerative diseases of blood vessels. In *Vascular Pathology* (Stehbens, W.E. and Lie, J.T., eds), pp. 175–269, Chapman & Hall Medical
- 148 Ravnskov, U. and McCully, K.S. (2009) Vulnerable plaque formation from obstruction of *vasa vasorum* by homocysteinylated and oxidized lipoprotein aggregates complexed with microbial remnants and LDL autoantibodies. *Annal. Clin. Lab. Sci.* 39, 3–16
- 149 McCully, K.S. (1993) Chemical pathology of homocysteine. I. Atherogenesis. *Annal. Clin. Lab. Sci.* 23, 477–493
- 150 McCully, K.S. (2011) Chemical pathology of homocysteine. V. Thioretinamide, thioretinaco, and cystathionine synthase function in degenerative diseases. *Annal. Clin. Lab. Sci.* 41, 301–314
- 151 Velican, C. and Velican, D. (1981) Coronary intimal necrosis occurring as an early stage of atherosclerotic involvement. *Atherosclerosis* 39, 479–496
- 152 Gutstein, W.H. (1999) Vasospasm, vascular injury, and atherogenesis: a perspective. *Hum. Pathol.* 30, 365–371
- 153 Scotland, R. et al. (1999) On the regulation of tone in *vasa vasorum*. *Cardiovasc. Res.* 41, 237–245
- 154 Scotland, R.S. et al. (2000) Endogenous factors involved in regulation of tone of arterial *vasa vasorum*: implications for conduit vessel physiology. *Cardiovasc. Res.* 46, 403–411
- 155 Seneff, S. et al. (2015) A novel hypothesis for atherosclerosis as a cholesterol sulfate deficiency syndrome. *Theor. Biol. Med. Model.* 12, 9
- 156 Ross, R. and Glomset, J.A. (1973) Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. *Science* 180, 1332–1339
- 157 Ross, R. et al. (1974) A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells *in vitro*. *Proc. Natl. Acad. Sci. U. S. A.* 71, 1207–1210
- 158 Ross, R. (1975) Smooth muscle cell and atherosclerosis. *Verh. Dtsch. Ges. Inn. Med.* 81, 843–847
- 159 Ross, R. and Glomset, J.A. (1976) The pathogenesis of atherosclerosis (first of two parts). *N. Engl. J. Med.* 295, 369–377
- 160 Ross, R. and Glomset, J.A. (1976) The pathogenesis of atherosclerosis (second of two parts). *N. Engl. J. Med.* 295, 420–425
- 161 Ross, R. and Harker, L. (1976) Hyperlipidemia and atherosclerosis. *Science* 193, 1094–1100
- 162 Ross, R. (1979) The pathogenesis of atherosclerosis. *Mech. Ageing Dev.* 9, 435–440
- 163 Ross, R. (1979) The arterial wall and atherosclerosis. *Annu. Rev. Med.* 30, 1–15
- 164 Ross, R. (1981) George Lyman Duff Memorial Lecture, Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components. *Arteriosclerosis* 1, 293–311
- 165 Ross, R. (1981) A changing approach to atherosclerosis. Results of basic research. *Acta Cardiol.* 36, 79–81
- 166 Ross, R. (1981) Atherosclerosis: a question of endothelial integrity and growth control of smooth muscle. *Harvey Lect.* 77, 161–182
- 167 Ross, R. (1983) Recent progress in understanding atherosclerosis. *J. Am. Geriatr. Soc.* 31, 231–235
- 168 Ross, R. (1984) Atherosclerosis. *J. Cardiovasc. Pharmacol.* 6 (Suppl. 4), 714–719
- 169 Ross, R. et al. (1984) The role of endothelial injury and platelet and macrophage interactions in atherosclerosis. *Circulation* 70 III177–82
- 170 Ross, R. (1986) The pathogenesis of atherosclerosis – an update. *N. Engl. J. Med.* 314, 488–500
- 171 Ross, R. (1986) Endothelium, monocytes, platelets, and atherosclerosis. *Monogr. Atheroscler.* 14, 169–172
- 172 Ross, R. (1987) Growth factors in the pathogenesis of atherosclerosis. *Acta Med. Scand. Suppl.* 715, 33–38
- 173 Ross, R. (1990) Mechanisms of atherosclerosis – a review. *Adv. Nephrol. Necker. Hosp.* 19, 79–86
- 174 Ross, R. (1993) Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. *Am. J. Pathol.* 143, 987–1002
- 175 Ross, R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 362, 801–809
- 176 Ross, R. (1993) Atherosclerosis: current understanding of mechanisms and future strategies in therapy. *Transplant. Proc.* 25, 2041–2043
- 177 Ross, R. (1995) Growth regulatory mechanisms and formation of the lesions of atherosclerosis. *Ann. N. Y. Acad. Sci.* 748 1–4; discussion 4–6
- 178 Ross, R. (1995) Cell biology of atherosclerosis. *Annu. Rev. Physiol.* 57, 791–804
- 179 Ross, R. (1999) Atherosclerosis – an inflammatory disease. *N. Engl. J. Med.* 340, 115–126
- 180 Ross, R. et al. (1977) Response to injury and atherogenesis. *Am. J. Pathol.* 86, 675–684
- 181 Wissler, R.W. (1991) Morphological characteristics of the developing atherosclerotic plaque. Animal studies and studies of lesions from young people. *Atheroscler. Rev.* 23, 91–103
- 182 Carew, T.E. et al. (1984) Measurement *in vivo* of irreversible degradation of low-density lipoprotein in the rabbit aorta – predominance of intimal degradation. *Arteriosclerosis* 4, 214–224
- 183 Williams, K.J. and Tabas, I. (1998) The response-to-retention hypothesis of atherogenesis reinforced. *Curr. Opin. Lipidol.* 9, 471–474
- 184 Tabas, I. et al. (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis – update and therapeutic implications. *Circulation* 116, 1832–1844
- 185 Tabas, I. (2011) Pulling down the plug on atherosclerosis: finding the culprit in your heart. *Nat. Med.* 17, 791–793
- 186 Tabas, I. et al. (2015) Recent insights into the cellular biology of atherosclerosis. *J. Cell Biol.* 209, 13–22
- 187 Tabas, I. et al. (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. *Circulation* 116, 1832–1844
- 188 Jonasson, L. et al. (1986) Regional accumulations of T-cells, macrophages, and smooth-muscle cells in the human atherosclerotic plaque. *Arteriosclerosis* 6, 131–138
- 189 Jonasson, L. et al. (1985) Expression of class-II transplantation antigen on vascular smooth-muscle cells in human atherosclerosis. *J. Clin. Invest.* 76, 125–131
- 190 Libby, P. et al. (2009) Inflammation in atherosclerosis: from pathophysiology to practice. *J. Am. Coll. Cardiol.* 54, 2129–2138
- 191 Winternitz, M.C., Thomas, R.M., LeCompte, P.M., (eds) (1938) *The Biology of Arteriosclerosis*, C.C. Thomas
- 192 LeCompte, P.M. (1967) Reactions of the *vasa vasorum* in vascular disease. In *Cowdry's Arteriosclerosis: A Survey of the Problem* (Blumenthal, H.T., ed.), pp. 212–224, Thomas

- 193 Barger, A.C. *et al.* (1984) Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. *N. Engl. J. Med.* 310, 175–177
- 194 Barger, A.C. and Beeuwkes, R. (1990) Rupture of coronary *vasa vasorum* as a trigger of acute myocardial infarction. *Am. J. Cardiol.* 66, G41–G43
- 195 Kumamoto, M. *et al.* (1995) Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. *Hum. Pathol.* 26, 450–456
- 196 Sueishi, K. *et al.* (1997) Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. *Ann. N. Y. Acad. Sci.* 811 (311–322), 322–314
- 197 Nakano, T. *et al.* (2005) Angiogenesis and lymphangiogenesis and expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. *Hum. Pathol.* 36, 330–340
- 198 Neufeld, H.N. *et al.* (1962) Coronary arteries in fetuses, infants, juveniles, and young adults. *Lab. Invest.* 11, 837–844
- 199 Williams, J.K. and Heistad, D.D. (1996) Structure and function of *vasa vasorum*. *Trends Cardiovasc. Med.* 6, 53–57
- 200 Moreno, P.R. *et al.* (2006) Neovascularization in human atherosclerosis. *Circulation* 113, 2245–2252
- 201 Pels, K. *et al.* (1997) Arterial wall neovascularization – potential role in atherosclerosis and restenosis. *Jpn. Circ. J.* 61, 893–904
- 202 Atkinson, C. *et al.* (2005) Angiogenesis occurs within the intimal proliferation that characterizes transplant coronary artery vasculopathy. *J. Heart Lung Transplant.* 24, 551–558
- 203 Vink, A. *et al.* (2002) Morphometric and immunohistochemical characterization of the intimal layer throughout the arterial system of elderly humans. *J. Anat.* 200, 97–103
- 204 Tracy, R.E. *et al.* (2002) The action of aging upon coronary intima and renal microvasculature in USA and Andes populations. *Mech. Ageing Dev.* 123, 327–339
- 205 Wolinsky, H. and Glagov, S. (1967) Nature of species differences in the medial distribution of aortic *vasa vasorum* in mammals. *Circ. Res.* 20, 409–421
- 206 Subbotin, V.M. (2012) Neovascularization of coronary tunica intima (DIT) is the cause of coronary atherosclerosis. Lipoproteins invade coronary intima via neovascularization from adventitial *vasa vasorum*, but not from the arterial lumen: a hypothesis. *Theor. Biol. Med. Model.* 9, 11
- 207 Libby, P. (2005) The forgotten majority: unfinished business in cardiovascular risk reduction. *J. Am. Coll. Cardiol.* 46, 1225–1228
- 208 Kones, R. and Rumana, U. (2015) Current treatment of dyslipidemia: a new paradigm for statin drug use and the need for additional therapies. *Drugs* 75, 1187–1199
- 209 Virmani, R. *et al.* (2005) Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. *Arterioscler. Thromb. Vasc. Biol.* 25, 2054–2061
- 210 Moulton, K.S. (2001) Plaque angiogenesis and atherosclerosis. *Curr. Atheroscler. Rep.* 3, 225–233
- 211 Moulton, K.S. *et al.* (2003) Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. *Proc. Natl. Acad. Sci. U. S. A.* 100, 4736–4741
- 212 Fleiner, M. *et al.* (2004) Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. *Circulation* 110, 2843–2850
- 213 Moreno, P.R. *et al.* (2004) Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. *Circulation* 110, 2032–2038
- 214 Kakadiaris, I.A. *et al.* (2010) *Vasa vasorum* imaging. In *Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment* (Naghavi, M., ed.), pp. 507–516, Humana Press
- 215 Kolodgie, F.D. *et al.* (2007) Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? *J. Am. Coll. Cardiol.* 49, 2093–2101
- 216 Raggi, P. (2015) Coronary atherosclerosis: an intra or extra luminal disease? *Atherosclerosis* 243, 344–345
- 217 Raggi, P. (2014) Epicardial adipose tissue and progression of coronary artery calcium cause and effect or simple association? *JACC Cardiovasc. Imaging* 7, 917–919
- 218 Hayden, M.R. and Tyagi, S.C. (2004) *Vasa vasorum* in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. *Cardiovasc. Diabetol.* 3, 1
- 219 van den Oord, S.C.H. *et al.* (2014) Assessment of carotid atherosclerosis, intraplaque neovascularization, and plaque ulceration using quantitative contrast-enhanced ultrasound in asymptomatic patients with diabetes mellitus. *Eur. Heart J. Cardiovasc. Imaging* 15, 1213–1218
- 220 Ruiz, E.G.M. *et al.* (2012) Analysis of contrast-enhanced intravascular ultrasound images for the assessment of coronary plaque neoangiogenesis: another step closer to the identification of the vulnerable plaque. *Curr. Pharm. Des.* 18, 2207–2213
- 221 Orasanu, G. and Putzky, J. (2009) The pathologic continuum of diabetic vascular disease. *J. Am. Coll. Cardiol.* 53, S35–S42
- 222 Michel, J-B. *et al.* (2011) Intraplaque haemorrhages as the trigger of plaque vulnerability. *Eur. Heart J.* <http://dx.doi.org/10.1093/eurheartj/ehr054>
- 223 Sluimer, J.C. *et al.* (2009) Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. *J. Am. Coll. Cardiol.* 53, 1517–1527
- 224 Cliff, W.J. and Schoefl, G.I. (1983) Pathological vascularization of the coronary intima. *Ciba Found. Symp.* 100, 207–221
- 225 Takano, M. *et al.* (2009) Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography. *J. Am. Coll. Cardiol.* 55, 26–32
- 226 Sarkisov, D.S. *et al.* (1989) Morphogenesis of intimal thickening in nonspecific aortoarteritis. *Hum. Pathol.* 20, 1048–1056
- 227 Herrmann, J. *et al.* (2001) Coronary *vasa vasorum* neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. *Cardiovasc. Res.* 51, 762–766
- 228 Regar, E. *et al.* (2005) Images in cardiovascular medicine. Optical coherence tomography findings at 5-year follow-up after coronary stent implantation. *Circulation* 112, e345–e346
- 229 Langheinrich, A.C. *et al.* (2007) *Vasa vasorum* and atherosclerosis – *Quid novi?* *Thromb. Haemost.* 97, 873–879
- 230 Hildebrandt, H.A. *et al.* (2008) Differential distribution of *vasa vasorum* in different vascular beds in humans. *Atherosclerosis* 199, 47–54
- 231 Heistad, D.D. and Armstrong, M.L. (1986) Blood-flow through *vasa vasorum* of coronary-arteries in atherosclerotic monkeys. *Arteriosclerosis* 6, 326–331
- 232 Shah, M. and Sikkel, M.B. (2013) Coronary artery disease and age: beyond atherosclerosis. *J. Physiol.* 591, 5807–5808
- 233 Deopujari, R. and Dixit, A. (2010) The study of age related changes in coronary arteries and its relevance to the atherosclerosis. *J. Anat. Soc. India* 59, 192–196
- 234 Monahan, K.D. *et al.* (2013) Contribution of sympathetic activation to coronary vasodilatation during the cold pressor test in healthy men: effect of ageing. *J. Physiol.* 591, 2937–2947
- 235 Stary, H.C. (1974) Proliferation or arterial cells in atherosclerosis. In *Arterial Mesenchyme and Arteriosclerosis*, (vol. 43) (Wagner, W.D. and Clarkson, T.B., eds) pp. 59–81, Plenum Press
- 236 Friedman, M. (1969) *Pathogenesis of Coronary Artery Disease*. Blakiston Division, McGraw-Hill
- 237 Sampaio, J.A.F.D. *et al.* (2006) Incidência de aterosclerose em artérias radiais de cadáveres. *Rev. Brasil. Cirurgia Cardiovasc.* 21, 165–172 (in Portuguese)
- 238 Barry, M. *et al.* (2007) Histologic study of coronary, radial, ulnar, epigastric and internal thoracic arteries: application to coronary artery bypass grafts. *Surg. Radiol. Anat.* 29, 297–302
- 239 Kolodgie, F.D. *et al.* (2007) Is pathologic intimal thickening the key to understanding early plaque progression in human atherosclerotic disease? *Arterioscler. Thromb. Vasc. Biol.* 27, 986–989
- 240 Otsuka, F. *et al.* (2015) Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: a pathology study. *Atherosclerosis* 241, 772–782
- 241 Osborn, G.R. and Davis, R., (eds) (1963) *The Incubation Period of Coronary Thrombosis*, Butterworths
- 242 Semenza, G.L. (2009) Regulation of vascularization by hypoxia-inducible factor 1. *Ann. N. Y. Acad. Sci.* 1177, 2–8
- 243 Marti, H.J. *et al.* (2000) Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. *Am. J. Pathol.* 156, 965–976
- 244 Laurenzana, A. *et al.* (2015) Endothelial progenitor cells in sprouting angiogenesis: proteases pave the way. *Curr. Mol. Med.* 15, 606–620
- 245 Brown, L.F. *et al.* (1989) Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. *Am. Rev. Respir. Dis.* 140, 1104–1107
- 246 Nagy, J.A. *et al.* (1989) Pathogenesis of tumor stroma generation – a critical role for leaky blood-vessels and fibrin deposition. *Biochim. Biophys. Acta* 948, 305–326
- 247 Jain, R.K. and Munn, L.L. (2000) Leaky vessels? Call Ang1! *Nat. Med.* 6, 131–132
- 248 Kaplan, H.J. (2007) Anatomy and function of the eye. *Chem. Immunol. Allergy* 92, 4–10
- 249 Taylor, A.W. (2016) Ocular immune privilege and transplantation. *Front. Immunol.* 7, 37

- 250 Falk, E. (2006) Pathogenesis of atherosclerosis. *J. Am. Coll. Cardiol.* 47 (8 Suppl.), C7–C12
- 251 Finn, A.V. *et al.* (2009) Pharmacotherapy of coronary atherosclerosis. *Expert Opin. Pharmacother.* 10, 1587–1603
- 252 Finn, A.V. *et al.* (2010) Concept of vulnerable/unstable plaque. *Arterioscler. Thromb. Vasc. Biol.* 30, 1282–1292
- 253 Ruben, M. (1981) Corneal vascularization. *Int. Ophthalmol. Clin.* 21, 27–38
- 254 Azar, D.T. (2006) Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). *Trans. Am. Ophthalmol. Soc.* 104, 264–302
- 255 Knop, E. and Knop, N. (2007) Anatomy and immunology of the ocular surface. *Chem. Immunol. Allergy* 92, 36–49
- 256 Cogan, D.C. and Kuwabara, T. (1958) Lipid keratopathy and atheroma. *Trans. Am. Ophthalmol. Soc.* 56, 109–119
- 257 Gupta, D. and Illingworth, C. (2011) Treatments for corneal neovascularization: a review. *Cornea* 30, 927–938
- 258 Epstein, R.J. *et al.* (1987) Corneal neovascularization. Pathogenesis and inhibition. *Cornea* 6, 250–257
- 259 Al-Abdullah, A.A. and Al-Assiri, A. (2011) Resolution of bilateral corneal neovascularization and lipid keratopathy after photodynamic therapy with verteporfin. *Optometry* 82, 212–214
- 260 Chu, H.S. *et al.* (2011) Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition. *Cornea* 30, 60–66
- 261 Yeung, S.N. *et al.* (2011) Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. *Cornea* 30, 1110–1114
- 262 Loeffler, K.U. and Seifert, P. (2005) Unusual idiopathic lipid keratopathy: a newly recognized entity? *Arch. Ophthalmol.* 123, 1435–1438
- 263 Duran, J.A. and Rodriguez-Ares, M.T. (1991) Idiopathic lipid corneal degeneration. *Cornea* 10, 166–169
- 264 Arentsen, J.J. (1986) Corneal neovascularization in contact lens wearers. *Int. Ophthalmol. Clin.* 26, 15–23
- 265 Oh, J.Y. *et al.* (2009) Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. *Cornea* 28, 1070–1073
- 266 Peter, J. *et al.* (2004) Fluorescein angiographic monitoring of corneal vascularization in lipid keratopathy. *Clin. Exp. Ophthalmol.* 32, 78–80
- 267 Chen, W.L. *et al.* (2014) Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization. *PLoS One* 9, e94205
- 268 Chu, H.-S. *et al.* (2013) Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab. *Cornea* 32, 1446–1453
- 269 Elbaz, U. *et al.* (2015) Corneal fine needle diathermy with adjuvant bevacizumab to treat corneal neovascularization in children. *Cornea* 34, 773–777
- 270 Kazmierczak, Z. and Pandzioch, Z. (1981) Chromatographic identification of lipids from the aqueous eye humor. *Microchem. J.* 26, 399–401
- 271 Koutselinis, A. *et al.* (1978) Major lipid classes in aqueous-humor after death. *Metabolic Ophthalmol.* 2, 19–21
- 272 Kalofoutis, A. *et al.* (1977) Chemistry of death. 2. Phospholipid composition of aqueous-humor after death. *Forensic Sci.* 9, 229–232
- 273 Olin, D.D. *et al.* (1976) Lipid-laden aqueous-humor associated with anterior uveitis and concurrent hyperlipemia in 2 dogs. *J. Am. Veterinary Med. Assoc.* 168, 861–864
- 274 Schmidt-Martens, F.W. (1972) Lipids in the aqueous humor of the cattle eye and their role as potential nutritive substrates for the cornea. *Bericht über die Zusammenkunft. Deutsche Ophthalmologische Gesellschaft* 71, 91–95 (in German)
- 275 Varma, S.D. and Reddy, V.N. (1972) Phospholipid composition of aqueous humor, plasma and lens in normal and alloxan diabetic rabbits. *Exp. Eye Res.* 13, 120–125
- 276 Silva-Araujo, A. *et al.* (1993) Primary lipid keratopathy: a morphological and biochemical assessment. *Br. J. Ophthalmol.* 77, 248–250
- 277 Onda, M. *et al.* (2002) Expression of lumican in thickened intima and smooth muscle cells in human coronary atherosclerosis. *Exp. Mol. Pathol.* 72, 142–149
- 278 Hultgardh-Nilsson, A. *et al.* (2015) The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis. *J. Int. Med.* 278, 447–461
- 279 Moschcowitz, E. (1950) Hyperplastic arteriosclerosis versus atherosclerosis. *J. Am. Med. Assoc.* 143, 861–865
- 280 Shapiro, W.D. (1951) Coronary disease in the young. Dissertation. In *Medicine*. p. 56, University of Wisconsin
- 281 [No authors listed] (1955) REPORT of Committee on Nomenclature of The American Society for the Study of Arteriosclerosis; tentative classification of arteriopathies. *Circulation* 12, 1065–1067
- 282 Koba, S. *et al.* (2000) Role of small dense low-density lipoprotein in coronary artery disease patients with normal plasma cholesterol levels. *J. Cardiol.* 36, 371–378
- 283 Appleby, P.N. *et al.* (1999) The Oxford Vegetarian Study: an overview. *Am. J. Clin. Nutr.* 70, 525–531S
- 284 Thorogood, M. (1994) Vegetarianism, coronary disease risk factors and coronary heart disease. *Curr. Opin. Lipidol.* 5, 17–21
- 285 Lands, B. (2009) Planning primary prevention of coronary disease. *Curr. Atheroscler. Rep.* 11, 272–280
- 286 Bernard, C., ed. (1957) *An Introduction to the Study of Experimental Medicine*, Dorer, New York
- 287 Stehbens, W.E. (1985) The concept of cause in disease. *J. Chronic Dis.* 38, 947–950
- 288 Alexopoulos, N. *et al.* (2013) Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). *J. Am. Coll. Cardiol.* 61, 1956–1961
- 289 Raggi, P. (2014) Epicardial adipose tissue and progression of coronary artery calcium: cause and effect or simple association? *JACC Cardiovasc. Imaging* 7, 917–919
- 290 Fong, G.-H. (2015) Potential contributions of intimal and plaque hypoxia to atherosclerosis. *Curr. Atheroscler. Rep.* 17, 510